Biotech startup Tahoe Therapeutics raised $30 million to develop AI models of living human cells, contributing to efforts to sequence over a billion cells for drug discovery applications. Despite some critique regarding preliminary validation, the funding signals major investment interest in computational biology and machine learning approaches to accelerative biomedical research. Tahoe joins initiatives like the Chan Zuckerberg Initiative in building comprehensive cell atlases for precision medicine.